Harmony Biosciences Holdings, Inc. (HRMY)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Harmony Biosciences Holdings, Inc. (HRMY)
Go deeper and ask any question about HRMY
Company Performance
Current Price
as of Sep 13, 2024$38.91
P/E Ratio
19.92
Market Cap
$2.21B
Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Metrics
Overview
- HQPlymouth Meeting, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerHRMY
- Price$38.91+3.05%
Trading Information
- Market Cap$2.21B
- Float54.02%
- Average Daily Volume (1m)288,989
- Average Daily Volume (3m)379,661
- EPS$1.98
Company
- Revenue$656.11M
- Rev Growth (1yr)28.76%
- Net Income$11.59M
- Gross Margin77.95%
- EBITDA Margin15.86%
- EBITDA$27.41M
- EV$1.61B
- EV/Revenue2.45
- P/E19.92
- P/S3.41
Documents
SEC Filings
Earnings Calls
Factset Street Account